News

Net profit of Corona Remedies rose 30.11% to Rs 60.11 crore in the quarter ended June 2026 as against Rs 46.20 crore during the previous quarter ended June 2025. Sales rose 21.90% to Rs 422.43 crore in the quarter ended June 2026 as against Rs 346.54 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales422.43346.54 22 OPM %22.0520.08 - PBDT93.6069.61 34 PBT80.3660.69 32 NP60.1146.20 30 Powered by Capital Market - Live News

Corona Remedies will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Corona Remedies announced that the 22th Annual General Meeting(AGM) of the company will be held on 9 July 2026.

Corona Remedies announced that the Board of Directors of the Company at its meeting held on 11 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Net profit of Corona Remedies rose 43.68% to Rs 45.33 crore in the quarter ended March 2026 as against Rs 31.55 crore during the previous quarter ended March 2025. Sales rose 20.23% to Rs 353.09 crore in the quarter ended March 2026 as against Rs 293.69 crore during the previous quarter ended March 2025.For the full year,net profit rose 23.88% to Rs 185.12 crore in the year ended March 2026 as against Rs 149.43 crore during the previous year ended March 2025. Sales rose 17.28% to Rs 1403.18 crore in the year ended March 2026 as against Rs 1196.42 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales353.09293.69 20 1403.181196.42 17 OPM %17.5618.46 -20.9120.06 - PBDT65.0353.65 21 297.39235.69 26 PBT54.7443.61 26 259.52198.53 31 NP45.3331.55 44 185.12149.43 24 Powered by Capital Market - Live News